You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

COVID-19: Get the latest updates or take a self-assessment.

The Continued Use of Trastuzumab Beyond Disease Progression in Patients with Metastatic Breast Cancer

Patient Population

Adult women with HER2-overexpressing MBC whose disease has progressed following prior treatment with trastuzumab.

Research Question(s)

Does the continued use of trastuzumab (alone or in combination with other systemic therapies) after disease progression improve outcomes in women with metastatic breast cancer (MBC) compared to best supportive care or systemic therapy without trastuzumab?

Outcomes of interest include overall survival (OS), progression-free survival (PFS), objective response rate (ORR), quality of life (QOL), and adverse events.

pdf download pebcced13f.pdf
Modality: 

Biological Therapy

PEBC: 

PEBC

Guideline Identifier: 

CED 13

Cancer Continuum: 

Treatment

Cancer Type: 

Breast

Type of Content: 

Guidelines & Advice

Clinical

Authors:  Y. Madarnas A.E. Haynes A. Eisen Universal Date:  2009-06-30 00:00:00